Where Will Citius Pharmaceuticals Inc (CTXR) Stock Go Next After It Is Down 0.95% in a Week?

Tuesday, September 29, 2020 3:20 PM | InvestorsObserver Analysts

Citius Pharmaceuticals Inc (CTXR) stock has fallen 0.95% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.

Sentiment Score - ,bullish
Citius Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CTXR!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.

Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.

InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.

Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With CTXR Stock Today?

Citius Pharmaceuticals Inc (CTXR) stock is down -0.96% while the S&P 500 has gained 1.61% as of 3:06 PM on Tuesday, Sep 29. CTXR has fallen -$0.01 from the previous closing price of $1.05 on volume of 1,842,898 shares. Over the past year the S&P 500 has gained 12.59% while CTXR has gained 36.84%. CTXR lost -$0.55 per share in the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Citius Pharmaceuticals Inc click here.

More About Citius Pharmaceuticals Inc

Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the development and commercialization of anti-infective products, adjunctive cancer care, and unique prescription products. Citius is currently advancing two proprietary product candidates, Mino-Lok product and a Hydrocortisone-Lidocaine formulation. Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections. The company's Hydrocortisone-Lidocaine provides anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids. It is primarily operating within the critical care and cancer care market segments.

Click Here to get the full Stock Score Report on Citius Pharmaceuticals Inc (CTXR) Stock.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Related Companies